CASP1 and type 2 diabetes mellitus: Dapagliflozin has been proved to be able to block NLRP3–caspase 1 signaling, reducing the production of IL-1beta in diabetic ApoE−/− mice and T2DM rodent models [67,71]; empagliflozin blocks the proliferation of the smooth muscle cells inhibiting the production of IL-1beta and IL-18 acting in NLRP3–caspase 1 signaling [69], reducing the production of ROS responsible for the progression of vascular damage.